HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Henrik K. Kjaergard Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kjaergard, H. K. Articles by Trumbull, H. R. Search for Related Content PubMed PubMed Citation Articles by Kjaergard, H. K. Articles by Trumbull, H. R.

Ann Thorac Surg 2000;69:1173-1175
© 2000 The Society of Thoracic Surgeons

---

ORIGINAL ARTICLES: CARDIOVASCULAR

Bleeding from the sternal marrow can be stopped using vivostat patient-derived fibrin sealant

^a Department of Cardiothoracic Surgery, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Address reprint requests to Dr Kjaergard, Department of Cardiothoracic Surgery, Gentofte Hospital, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark
e-mail: hekja{at}gentoftehosp.kbhamt.dk

Background. Median sternotomy is the most important method of access to the heart. Bleeding from the sternal marrow may become significant, especially in elderly patients. Vivostat (ConvaTec, a Bristol-Myers Squibb Company, Skillman, NJ) patient-derived fibrin sealant is biocompatible and easily applied to the sternal marrow using the Vivostat Spraypen applicator.

Methods. Thirty patients undergoing elective cardiac operation were randomized to receive Vivostat fibrin sealant applied to either the right or left side of the sternum immediately after median sternotomy, with the untreated side serving as control.

Results. The average time to hemostasis was 43 seconds after treatment with Vivostat and 180 seconds on the control sides (p < 0.001). At the end of the operation, complete hemostasis was observed on 24 of 30 sides treated with Vivostat compared with on 4 of 30 of the control sides (p < 0.001). The average volume of sealant used to cover one side of the sternum was 0.9 mL.

Conclusions. Vivostat patient-derived fibrin sealant is a biocompatible alternative to bone wax, with the results of this study showing that it provides effective control of bleeding after median sternotomy.

This article has been cited by other articles:

				D. D. Muehrcke, W. M. Shimp, and R. Aponte-Lopez Calcium phosphate cements improve bone density when used in osteoporotic sternums. Ann. Thorac. Surg., November 1, 2009; 88(5): 1658 - 1661. [Abstract] [Full Text] [PDF]

				C. Aratari, A. Manche, L. Ferretti, and M. Fusella Cardiopulmonary bypass line sternal wrapping for protection and haemostasis Interactive CardioVascular and Thoracic Surgery, August 1, 2009; 9(2): 147 - 149. [Abstract] [Full Text] [PDF]

				J. Prziborowski, M. Hartrumpf, U. A. Stock, R. U. Kuehnel, and J. M. Albes Is Bonewax Safe and Does It Help? Ann. Thorac. Surg., March 1, 2008; 85(3): 1002 - 1006. [Abstract] [Full Text] [PDF]

				D. D. Muehrcke, P. Barberi, and W. M. Shimp Calcium Phosphate Cements to Control Bleeding in Osteoporotic Sternums Ann. Thorac. Surg., July 1, 2007; 84(1): 259 - 261. [Abstract] [Full Text] [PDF]

				H. Mair, A. Schutz, P. Lamm, and B. Reichart Control of bleeding from fragile sternum with a resorbable hemostyptic Ann. Thorac. Surg., February 1, 2001; 71(2): 759 - 760. [Full Text] [PDF]